文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

PCSK9抑制剂对伴冠心病史的急性缺血性卒中患者早期神经功能恶化的影响:中国大连随机对照试验研究方案

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China.
PubMed 文献 · Trials · 2025-01-06

本研究为前瞻性、随机、平行组、终点盲法、单中心临床试验,拟纳入156例症状发作24小时内且有冠心病史的急性缺血性卒中患者,按1:1随机分配至PCSK9抑制剂联合他汀组或他汀单药组,试验持续90天,评估PCSK9抑制剂对早期神经功能恶化的预防效果。

要点

  • 拟纳入156例伴冠心病史的急性缺血性卒中患者,随机1:1分至PCSK9抑制剂联合他汀组或他汀单药组。
  • PI组接受依洛尤单抗联合瑞舒伐他汀钙片,AT组仅口服瑞舒伐他汀钙片。
  • 试验持续90天,于入组后第1、7、30、90天进行综合检查与评估。

核心结论

  • 本研究旨在探讨PCSK9抑制剂对伴冠心病史的急性缺血性卒中患者早期神经功能恶化的潜在预防作用。
  • 作者认为,若试验结果阳性,可能为降低早期神经功能恶化发生率、改善此类卒中患者短期预后提供新的临床策略。

研究设计与样本

  • 前瞻性、随机、平行组、终点盲法、单中心临床研究。
  • 计划纳入156例症状发作24小时内且有冠心病史的急性缺血性卒中患者,按1:1随机分配至PI组或AT组。
  • PI组接受依洛尤单抗联合瑞舒伐他汀钙片治疗,AT组仅口服瑞舒伐他汀钙片。
  • 试验持续90天,包括筛选、治疗干预和随访评估三个阶段,于入组后第1、7、30、90天进行评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early neurological deterioration (END) is a critical determinant influencing the short-term prognosis of acute ischemic stroke (AIS) patients and is associated with increased mortality rates among hospitalized individuals. AIS frequently coexists with coronary heart disease (CHD), complicating treatment and leading to more severe symptoms and worse outcomes. Shared risk factors between CHD and AIS, especially elevated low-density lipoprotein cholesterol (LDL-C), contribute to atherosclerosis and inflammation, which worsen brain tissue damage. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a promising treatment option. They effectively lower LDL-C levels and may help reduce END in AIS patients with CHD. This study aims to evaluate how effective PCSK9 inhibitors are in reducing END among this high-risk group and to provide new insights for treatment strategies. METHODS: This is a prospective, randomized, parallel-group, blinded-endpoint, single-center clinical study. A total of 156 AIS patients with a history of CHD and within 24 h from symptom onset will be recruited and randomized in a 1:1 allocation to either the PCSK9 inhibitor combined with statin treatment group (PI group) or the statin monotherapy group (AT group). The PI group will receive a combination therapy consisting of evolocumab and rosuvastatin calcium tablets, while the AT group will receive only oral rosuvastatin calcium tablets. The trial duration will last for 90 days and comprise three phases: screening, treatment intervention, and follow-up assessments. Participants will undergo comprehensive examinations and assessments on days 1, 7, 30, and 90 after enrollment. DISCUSSION: This study aims to investigate the potential preventive effects of PCSK9 inhibitors on END in AIS patients with a history of CHD. A positive outcome from this trial could provide novel clinical strategies for reducing the incidence of END and improving the short-term prognosis among these stroke patients. TRIAL REGISTRATION: China Clinical Trial Registry, ChiCTR2300078198. Registered on 30 November 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gong X, Yu X, Pu L, et al. Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China. Trials. 2025. PMID: 39762992. doi:10.1186/s13063-024-08709-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。